Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Atara Biotherapeutics, Inc. (ATRA) is a Biotechnology company based in US with a market capitalization of $77.8M. Revenue declined 6.3% year-over-year and free cash flow was negative at -$50.9M. This page tracks ATRA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 153 employees · IPO Oct 16, 2014
Valuation
Valuation & price
$9.58as of May 17, 2026· -47.0% vs 52w high
3.7
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$77.8M
Market cap
-6.3%
Revenue growth (YoY)
82.4%
Gross margin
-$50.9M
Free cash flow (USD)
$44.3M
Net debt
67.5%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 26, 2026Filing
CFO Appointment
- 8-K eventJun 12, 2026Filing
Director Appointment
- Insider sellMay 20, 2026Filing
Insider Sell $22KGrant-Huerta Yanina · Chief Accounting Officer · $22K
- Insider sellMay 20, 2026Filing
Insider Sell $48KNguyen AnhCo · Director, President and CEO · $47.8K
- 8-K eventMay 12, 2026Filing
Earnings Release
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- Insider buyMay 11, 2026Filing
Insider Buy $4.7MEcoR1 Capital, LLC · 10% Owner · $4.7M
- Insider sellMay 11, 2026Filing
Insider Sell $3.2MPanacea Innovation Ltd · 10% Owner · $3.2M
- 8-K eventMay 7, 2026Filing
Regulatory Update
- 8-K eventMay 1, 2026Filing
Delisting Notice
Questions
Frequently asked questions
What is Atara Biotherapeutics, Inc.'s market cap?
Atara Biotherapeutics, Inc. (ATRA) has a market capitalization of $77.8M.
What is ATRA's P/E ratio?
ATRA trades at a price-to-earnings ratio of 3.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
Are insiders buying ATRA stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 3 sells at Atara Biotherapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.